2013-09-17 11:01:30 - David Stokoe, Senior Scientist at Genentech to Present at the 3rd Cancer Epigenetics Conference on November 6-8, 2013 in San Francisco, CA
David Stokoe, Senior Scientist at Genentech to present on “Targeting Chromatin Modifiers to Overcome Resistance to Anti-Cancer Drugs” at the 3rd Cancer Epigenetics Conference on November 6-8, 2013 in San Francisco, CA by GTC.
David Stokoe will discuss how the identification of specific molecular abnormalities in human tumors has recently given rise to the development of novel targeted therapeutics. Some of these have shown dramatic responses in defined patient population expressing these abnormalities, including Gleevec, Herceptin, Tarceva and Zelboraf. Unfortunately, in almost all cases, resistance to these agents develops, thereby hampering full potential clinical benefit. There is emerging evidence that one common mechanism underlying resistance to many of these agents involves changes in the chromatin landscape, including altered methylation and
acetylation of key residues in Histone tails. Understanding the exact types of alterations, as well as the relevant modifying enzymes, represents a potential source of novel targets for therapeutic intervention. We have identified a requirement for specific histone modifying enzymes in establishing a state of reversible drug tolerance within a subpopulation of tumor cells. By combining targeted therapies with inhibitors of these enzymes, it is possible to prevent or delay the emergence of drug resistance. Through RNAi screening with a library that targets chromatin regulators, we have identified additional proteins required to engage the drug-tolerant state, which may represent additional targets for therapeutic intervention.
David Stokoe is a senior scientist at Genentech, working on epigenetic targets for oncology indications. He received his PhD at the University of Dundee under Philip Cohen, and pursued postdoctoral training in Frank McCormick’s lab at Onyx Pharmaceuticals. Following 10 years at UCSF, working on signal transduction pathways downstream of Ras and receptor tyrosine kinases, Dr Stokoe moved to Genentech, where he worked on Ras inhibitors and cancer genomics, before developing an interest in epigenetics.
GTC’s 3rd Cancer Epigenetics Conference, one of two parallel tracks of the 2nd Cancer Summit – Novel Approaches to Drug Discovery on November 6-8 in San Francisco, CA, is the only cancer epigenetics conference that brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.
Below are the sessions of the Cancer Epigenetics Conference:
I. Epigenetic Mechanisms in Cancer
II. Epigenetic Biomarkers and Diagnostics
III. Novel Epigenetic Targets in Early Development
IV. New Clinical Development of Epigenetic Drugs
V. Epigenetic Tools and Technologies
For more information, please visit www.gtcbio.com/cancerepigenetics